| Literature DB >> 28927372 |
Gunhild Nyborg1, Mette Brekke2, Jørund Straand2, Svein Gjelstad2, Maria Romøren2.
Abstract
BACKGROUND: Frail residents in the nursing home sector call for extra care in prescribing. The Norwegian General Practice Nursing Home (NORGEP-NH) list of 34 explicit criteria for potentially inappropriate medication use in nursing homes was developed explicitly for this population. The aim of this study was to employ the NORGEP-NH Criteria to study the extent of potentially inappropriate medication use among nursing home residents and explore possible associated factors.Entities:
Keywords: Drug safety; Elderly; Explicit criteria; NORGEP-NH; Nursing homes; Potentially inappropriate medication use; Psychotropic medications
Mesh:
Substances:
Year: 2017 PMID: 28927372 PMCID: PMC5606129 DOI: 10.1186/s12877-017-0608-z
Source DB: PubMed Journal: BMC Geriatr ISSN: 1471-2318 Impact factor: 3.921
Prevalence of PIMs per person according to the NORGEP-NH criteria
| No. of PIMs per person | NORGEP-NH A1+B2 + C3, prevalence (%), | NORGEP-NH A1+B2, prevalence (%) | No. of psychotropic drugs per person, prevalence (%) | |||
|---|---|---|---|---|---|---|
| Excl. drugs on demand | Incl. drugs on demand | Excl. drugs on demand | Incl. drugs on demand | Excl. drugs on demand | Incl. drugs on demand | |
| 0 | 108 (12.3) | 64 (7.3) | 495 (56.2) | 265 (30.1) | 267 (30.3) | 130 (14.8) |
| 1 | 253 (28.7) | 163 (18.5) | 163 (18.5) | 185 (21.0) | 290 (32.9) | 182 (20.7) |
| 2 | 211 (24.0) | 161 (18.3) | 136 (15.4) | 181 (20.5) | 196 (22.2) | 203 (23.0) |
| 3 | 142 (16.1) | 151 (17.1) | 63 (7.2) | 138 (15.7) | 86 (9.8) | 160 (18.2) |
| 4 | 80 (9.1) | 130 (14.8) | 20 (2.3) | 72 (8.2) | 37 (4.2) | 113 (12.8) |
| 5 | 52 (5.9) | 104 (11.8) | 3 (0.3) | 22 (2.5) | 4 (0.5) | 53 (6.0) |
| 6 | 26 (3.0) | 57 (6.5) | 0 | 13 (1.5) | 1 (0.1) | 29 (3.3) |
| 7 | 5 (0.6) | 29 (3.3) | 1 (0.1) | 2 (0.2) | 0 | 8 (0.9) |
| 8 | 3 (0.3) | 13 (1.5) | 0 | 3 (0.3) | 0 | 2 (0.2) |
| 9 | 0 | 3 (0.3) | 0 | 0 | 0 | 1 (0.1) |
| 10 | 1 (0.1) | 5 (0.6) | 0 | 0 | 0 | 0 |
| 11 | 0 | 1 (0.1) | 0 | 0 | 0 | 0 |
| SUM | 881 (100%) | 881 (100%) | 881 (100%) | 881 (100%) | 881 (100%) | 881 (100%) |
1A: Single substance criteria 2B: Combination criteria 3C: Deprescribing criteria
Number of people affected, with percentages
Sample characteristics
| Total number (%) in data set | Number with medication list (%). Included in study | Number without medication list (%). Not included in study | Mean (range) among those included in study | |
|---|---|---|---|---|
| Participants | 914 (100) |
| 33 (100) | |
| Gender: | ||||
| Female | 623 (68.2) | 604 (68.6) | 19 (57.6) | |
| Male | 291 (31.8) | 277 (31.4) | 14 (42.2) | |
| Age (years): | 85.9 (70–102) | |||
| ≤ 85 | 401 (43.9) | 382 (43.4) | 19 (57.6) | |
| > 85 | 513 (56.1) | 499 (56.6) | 14 (42.4) | |
| Institutions | 30 | 30a | 16a | |
| No. of beds | 1379 | 46.0b (12–124) | ||
| No. of incl. Cases | 881 (100) | 29.4b (3–170) | ||
| No. of NH doctors | 57 | 1.9b (1–6) |
aNo. of institutions represented among patients with/without medication lists. bPer institution
* significant at p<0.05
Prevalence of potentially inappropriate medication use in nursing home residents ≥70 years according to NORGEP-NH
| NORGEP-NHa List of Explicit Criteria | Freq., regular med. Only, in % | Freq., incl. PRNb medication, in % |
|---|---|---|
| A: Single Substance Criteria. The following should be avoided for regular use whenever possible: | ||
| 1. Combination analgesic with codeine/paracetamol | 0.8 | 6.8 |
| 2. Tricyclic antidepressants (TCAs) for depression | 0.9 | 0.9 |
| 3. NSAIDs | 1.1 | 7.7 |
| 4. First generation antihistamines | 4.5 | 6.0 |
| 5. Diazepam | 1.4 | 10.7 |
| 6. Oxazepam: Dosage >30 mg/day | 0.8 | N/A |
| 7. Zopiclone: Dosage >5 mg/day | 14.1 | N/A |
| 8. Nitrazepam | 2.8 | 3.6 |
| 9. Flunitrazepam | 0.3 | 0.3 |
| 10. Chlometiazole | 1.2 | 8.7 |
| 11. Regular use of hypnotics | 30.9 | N/A |
| B: Combination Criteria. The following drug combinations should be avoided whenever possible: | ||
| 12. Warfarin + NSAIDs | 0.0 | 0.5 |
| 13. Warfarin + SSRI/SNRI | 1.6 | 1.6 |
| 14. Warfarin + ciprofloxacin/ofloxacin/ erythromycin/ clarithromycin | 0.3 | 0.5 |
| 15. NSAIDs/coxibs + ACE-inhibitors/AT2-antagonists | 0.2 | 1.1 |
| 16. NSAIDs/coxibs + diuretics | 0.6 | 3.9 |
| 17. NSAIDs/coxibs + glucocorticoids | 0.0 | 0.0 |
| 18. NSAIDs/coxibs + SSRI/SNRIs | 0.2 | 2.0 |
| 19. ACE-inhibitors/AT2-antagonists + potassium or potassium-sparing diuretics | 1.9 | 1.9 |
| 20. Beta blocking agents + cardioselective calcium antagonists | 0.0 | 0.1 |
| 21. Erythromycin/clarithromycin + statins | 0.1 | 0.1 |
| 22. Bisphosphonate + proton pump inhibitors | 1.6 | 1.7 |
| 23. Concomitant use of three or more psychotropic drugs | 14.5 | 41.5 |
| 24. Tramadol + SSRIs | 1.4 | 6.1 |
| 25. Metoprolol + paroxetine/fluoxetine/bupropion | 0.0 | 0.0 |
| 26. Metformin + ACE-inhibitors/AT2-antagonists + diuretics | 1.0 | 1.0 |
| C: Deprescribing criteria. Need for continued use should be reassessed: | ||
| 27. Anti-psychotics | 10.3 | 14.2 |
| 28. Anti-depressants | 35.3 | 35.5 |
| 29. Urologic spasmolytics | 0.7 | 0.7 |
| 30. Anticholinesterase inhibitors | 5.9 | 6.0 |
| 31. Drugs that lower blood pressurec | 62.5 | 65.2 |
| 32. Bisphosphonates | 5.4 | 5.6 |
| 33. Statins | 12.1 | 12.1 |
| 34. General use of preventive medication | N/Ad | N/Ad |
aThe Norwegian General Practice criteria for assessing potentially inappropriate prescriptions to elderly patients in Nursing Homes. bPro re nata, drugs given as needed. cIncl. in the figures: All drugs that have the lowering of blood pressure as primary outcome (i.e. hypertensives). Excl. drugs with lower blood pressure as side effect, wanted or unwanted. dCriterion 34 on the NORGEP-NH list, “General use of preventive medication”, was not assessed in this paper, as information was lacking on whether medication was given for the purpose of treatment or prevention. Abbreviations: NSAIDs: Non-steroid anti-inflammatory drugs. SSRIs: Selective serotonin reuptake inhibitors. SRNIs: Selective norepinephrine reuptake inhibitors. Coxibs: Cyclooxygenase-2-selective inhibitors. ACE-inhibitors: Angiotensin-converting enzyme inhibitors. AT2-antagonists: Angiotensin II receptor antagonists
Factors associated with potentially inappropriate medications, and 3+ concomitant psychotropic medications according to NORGEP-NH Single Substance and Combination Criteriaa
| PIMs according to NORGEP-NH Criteria 1–26 | 3+ concomitant psychotropic drugs | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable | No. of residents n (valid cases, %) | Bivariate analyses OR (95% C.I.) |
| Multivariate analyses OR (95% C.I.) |
| Bivariate analyses OR (95% C.I.) |
| Multivariate analyses OR (95% C.I.) |
|
| Ageb
| 881 | 0.99 (0.97–1.01) | 0.34 | 0.98 (0.96–1.01) | 0.17 | 0.99 (0.96–1.02) | 0.59 | 0.98 (0.95–1.01) | 0.18 |
| Gender: n = 881 Male | 277 (31.4) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||
| Female | 604 (68.6) | 1.38 (1.02–1.86) |
| 1.60 (1.14–2.24) |
| 1.72 (1.09–2.71) |
| 1.79 (1.06–3.01) |
|
| Barthelc
| 314 (35.6) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||
| 6–10 | 259 (29.4) | 1.28 (0.91–1.80) | 0.16 | 1.36 (0.95–1.94) | 0.09 | 1.26 (0.75–2.10) | 0.38 | 1.41 (0.83–2.42) | 0.21 |
| 11–20 | 234 (26.6) | 1.30 (0.91–1.85) | 0.15 | 1.32 (0.91–1.92) | 0.15 | 1.83 (1.11–3.04) |
| 2.16 (1.25–3.73) |
|
| Falls: | 663 (75.3) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||
| Yes | 167 (19.0) | 1.09 (0.77–1.54) | 0.47 | 1.10 (0.76–1.36) | 0.60 | 1.84 (1.16–2.91) |
| 1.70 (1.03–2.80) |
|
| Deliriumd: | 807 (91.6) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||
| Yes | 70 (7.9) | 0.93 (0.56–1.55) | 0.78 | 0.95 (0.51–1.76) | 0.88 | 1.22 (0.62–2.42) | 0.57 | 1.21 (0.52–2.83) | 0.66 |
| Deathe: | 782 (88.8) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||
| Yes | 97 (11.0) | 0.75 (0.48–1.17) | 0.21 | 0.80 (0.47–1.36) | 0.41 | 0.97 (0.52–1.78) | 0.91 | 1.67 (0.82–3.38) | 0.16 |
| Ward: | 58 (6.6) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||
| Short-time | 158 (17.9) | 0.74 (0.30–1.39) | 0.44 | 0.87 (0.39–1.94) | 0.73 | 2.30 (0.54–9.87) | 0.26 | 2.75 (0.60–12.60) | 0.19 |
| Long-time | 364 (41.3) | 1.25 (0.52–2.35) | 0.57 | 1.61 (0.72–3.62) | 0.25 | 5.08 (1.27–20.23) |
| 7.48 (1.74–32.08) |
|
| Short−/longtime | 100 (11.4) | 1.56 (0.59–3.17) | 0.31 | 2.12 (0.86–5.26) | 0.10 | 5.92 (1.34–26.27) |
| 7.20 (1.51–34.36) |
|
| Dementia | 114 (12.9) | 1.11 (0.41–2.16) | 0.80 | 1.19 (0.50–2.83) | 0.70 | 7.24 (1.68–31.27) |
| 7.70 (1.68–35.32) |
|
| Palliative | 46 (5.2) | 1.51 (0.56–3.61) | 0.38 | 1.98 (0.73–5.40) | 0.18 | 1.88 (0.30–11.71) | 0.50 | 2.04 (0.30–13.99) | 0.47 |
aBivariate and multivariate mixed effects regression analyses stratified on the nursing home level. bContinuous variable. cNo. of residents in each tertile. dIn the course of the infection. eWithin 30 days of study inclusion
*significant at p<0.05
Regression model including all nursing home residents